Re: Aducanumab-Related ARIA: Paean or Lament?

Aducanumab-Related Amyloid-Related Imaging Abnormalities

(2022) Poul F. Høilund-Carlsen et al.   CLINICAL NUCLEAR MEDICINE

Commentary

(2022) Heidi R. Wassef et al.   CLINICAL NUCLEAR MEDICINE

Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches

(2022) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

(2021) Stephen Salloway et al.   JAMA Neurology

Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

(2019) Ebba Gløersen Müller et al.   PLoS One

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

(2016) Milos D. Ikonomovic et al.   Acta Neuropathologica Communications

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia